Untitled Letters: The Warning Letter's Quieter Cousin
An untitled letter cites violations that do not meet the threshold for a warning letter. It is FDA's initial correspondence saying it considers something to be in violation, without the escalation a warning letter carries.
The name is literal. A warning letter is titled "WARNING LETTER". An untitled letter has no such heading, and that absence is the distinction.
What separates the two
A warning letter is reserved for violations of regulatory significance, meaning those that may lead to enforcement action if not corrected promptly.
An untitled letter covers violations that do not reach that bar. Practically:
- It does not include a warning that failure to correct may result in enforcement.
- It does not usually require a response within 15 working days, though it requests one.
- It does not carry the same consequences for pending applications.
What it shares with a warning letter: FDA has put in writing that it considers you in violation, and the letter is a public document.
Where they are most common
Untitled letters are heavily concentrated in promotional communications. The Office of Prescription Drug Promotion issues them for material it considers false or misleading, and for most sponsors an untitled letter is the realistic enforcement outcome of an MLR failure rather than a warning letter.
They also appear in clinical investigator and IRB oversight, and occasionally in device promotion.
Why it still matters
It is public. Published, indexed, and found by anyone searching your company or product. A customer or partner performing diligence does not weigh the absence of a heading.
It establishes notice. FDA has told you in writing. A subsequent similar violation is no longer a first occurrence, and repeat conduct after an untitled letter is a common route to a warning letter.
It is fast to act on. The violations are usually narrower and more concrete than a warning letter's, which means correcting them properly is genuinely achievable rather than a quality system overhaul.
Responding
Treat it as a warning letter with a shorter list. Correct what is cited, say what you did, and address the systemic question of how the material was approved in the first place. For a promotional letter that means the MLR process, not just the piece.
Where the letter concerns material still in circulation, stopping its use is usually the first action and should be stated as such.
Frequently asked questions
What is an untitled letter?
FDA correspondence citing violations that do not meet the threshold of regulatory significance required for a warning letter.
How is it different from a warning letter?
It carries no statement that enforcement may follow, has no formal 15 working day response requirement, and reflects a lower level of concern.
Are untitled letters public?
Yes. They are published and are findable by anyone searching the company or product.
Do I have to respond?
FDA requests a response. Not responding removes your opportunity to close the matter and leaves the violation on the record.
Who issues most untitled letters?
The Office of Prescription Drug Promotion, for promotional communications, is the largest single source.
Can an untitled letter lead to a warning letter?
Yes. It establishes notice, and a repeat of the same conduct afterwards is a common route to escalation.